George A Calin

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
    Maria Ciccone
    Department of Experimental Therapeutics, Unit 1950, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX77030, USA
    Microrna 5:106-112. 2016
  2. doi request reprint Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis
    Martin Pichler
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res . 2016
  3. pmc Molecular pathways: microRNAs, cancer cells, and microenvironment
    Ioana Berindan-Neagoe
    Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania Department of Functional Genomics and Experimental Pathology, Ion Chiricuta The Oncology Institute, Cluj Napoca, Romania Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:6247-53. 2014
  4. pmc Fractal-like kinetics of intracellular enzymatic reactions: a chemical framework of endotoxin tolerance and a possible non-specific contribution of macromolecular crowding to cross-tolerance
    Catalin Vasilescu
    Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Street, Bucharest, Romania
    Theor Biol Med Model 10:55. 2013
  5. pmc Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway
    Lu Qian Wang
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Mol Cancer 12:173. 2013
  6. doi request reprint MicroRNAs and ceRNAs: therapeutic implications of RNA networks
    Dana Elena Giza
    The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Unit 1950, 1515 Holcombe Blvd, Houston, TX, 77030 4009, USA 1 713 792 5461 1 713 792 1204
    Expert Opin Biol Ther 14:1285-93. 2014
  7. ncbi request reprint MicroRNAs as cancer biomarkers
    Nazila Nouraee
    Department of Experimental Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA
    Microrna 2:102-17. 2013
  8. pmc Expression and function of micro-RNAs in immune cells during normal or disease state
    Esmerina Tili
    Ohio State University, Department of Molecular Virology, Immunology, Medical Genetics, Comprehensive Cancer Center, 385L Wiseman Hall, 400 W 12th Ave, Columbus, OH 43210, USA
    Int J Med Sci 5:73-9. 2008
  9. pmc MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis
    Catalin Vasilescu
    Department of Surgery, Fundeni Clinical Hospital, Bucharest, Romania
    PLoS ONE 4:e7405. 2009
  10. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013

Research Grants

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. ncbi request reprint MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
    Maria Ciccone
    Department of Experimental Therapeutics, Unit 1950, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX77030, USA
    Microrna 5:106-112. 2016
    ..Although few studies have shown the prognostic and predictive value of microRNA expression levels, their validation within prospective clinical trials is warranted...
  2. doi request reprint Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis
    Martin Pichler
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res . 2016
    ..Here, we followed a systematic approach on a global scale to identify miRNAs as clinical outcome predictors and further validated them in the clinical and experimental setting...
  3. pmc Molecular pathways: microRNAs, cancer cells, and microenvironment
    Ioana Berindan-Neagoe
    Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania Department of Functional Genomics and Experimental Pathology, Ion Chiricuta The Oncology Institute, Cluj Napoca, Romania Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:6247-53. 2014
    ..We further expand this in a more translational context and present miRNAs as predictors of treatment response, as crucial agents in targeted therapeutics, and as significant molecules to target...
  4. pmc Fractal-like kinetics of intracellular enzymatic reactions: a chemical framework of endotoxin tolerance and a possible non-specific contribution of macromolecular crowding to cross-tolerance
    Catalin Vasilescu
    Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Street, Bucharest, Romania
    Theor Biol Med Model 10:55. 2013
    ..We hypothesized that this particular type of enzyme kinetics may explain the development of ET phenomenon...
  5. pmc Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway
    Lu Qian Wang
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Mol Cancer 12:173. 2013
    ..The miR-9 family microRNAs have been identified as a tumor suppressor miRNA in cancers. We postulated that miR-9-1, miR-9-2 and miR-9-3 might be inactivated by DNA hypermethylation in chronic lymphocytic leukemia (CLL)...
  6. doi request reprint MicroRNAs and ceRNAs: therapeutic implications of RNA networks
    Dana Elena Giza
    The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Unit 1950, 1515 Holcombe Blvd, Houston, TX, 77030 4009, USA 1 713 792 5461 1 713 792 1204
    Expert Opin Biol Ther 14:1285-93. 2014
    ..ceRNAs are considered to be natural decoys of miRNA activity and can influence the expression of multiple miRNAs...
  7. ncbi request reprint MicroRNAs as cancer biomarkers
    Nazila Nouraee
    Department of Experimental Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA
    Microrna 2:102-17. 2013
    ..We further include a large compilation of PubMed data regarding microRNAs reported as diagnostic or prognostic cancer biomarkers in at least three studies. ..
  8. pmc Expression and function of micro-RNAs in immune cells during normal or disease state
    Esmerina Tili
    Ohio State University, Department of Molecular Virology, Immunology, Medical Genetics, Comprehensive Cancer Center, 385L Wiseman Hall, 400 W 12th Ave, Columbus, OH 43210, USA
    Int J Med Sci 5:73-9. 2008
    ..The purpose of this review is to discuss recent findings related with the expression and function of miRNAs in hematopoietic lineages...
  9. pmc MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis
    Catalin Vasilescu
    Department of Surgery, Fundeni Clinical Hospital, Bucharest, Romania
    PLoS ONE 4:e7405. 2009
    ....
  10. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013
    ....
  11. pmc Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer
    Robert S Hudson
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Mol Cancer 12:13. 2013
    ..We hypothesized that ucRNAs have unidentified roles in the pathogenesis of human prostate cancer. In a pilot study, we examined ucRNA expression profiles in human prostate tumors...
  12. ncbi request reprint MicroRNAs and cancer therapy - from bystanders to major players
    Cornelia Braicu
    Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
    Curr Med Chem 20:3561-73. 2013
    ..In this review, we focus on the roles of miRNAs in tumorigenesis, the rationale and strategies for the use of miRNA-based therapy for cancer, and the advantages and current challenges to their use. ..
  13. doi request reprint MicroRNAs as new biomarkers in oncology
    Riccardo Spizzo
    The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, 1515 Holcombe Blvd, Unit 36, Room Y6 6079, Houston, TX 77030, USA 1 713 792 5461 1 713 745 4528
    Expert Opin Med Diagn 2:115-27. 2008
    ..Finally, the authors consider the utility of miRNAs as tumor predisposition markers in cancer screening programs...
  14. pmc Decoy activity through microRNAs: the therapeutic implications
    Maria Inês Almeida
    The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Houston, TX 77030, USA
    Expert Opin Biol Ther 12:1153-9. 2012
    ..The same miRNA can have multiple mRNA targets, and the same mRNA can be regulated by various miRNAs...
  15. pmc Genetic control of mammalian T-cell proliferation with a synthetic RNA regulatory system - illusion or reality?
    Sang Kil Lee
    RNA interference and non coding RNA Center and the Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Genome Med 2:77. 2010
    ....
  16. pmc Breast cancer metastasis: a microRNA story
    Massimo Negrini
    Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Via Luigi Borsari, Ferrara 44100, Italy
    Breast Cancer Res 10:203. 2008
    ..The use of miRNAs as anticancer therapeutic agents is promising, and such fine molecular studies certainly help in bringing miRNAs closer to clinical practice...
  17. pmc Hematopoietic differentiation: a coordinated dynamical process towards attractor stable states
    Nadia Felli
    Department of Hematology, Oncology and Molecular Medicine Istituto Superiore di Sanità, Rome, Italy
    BMC Syst Biol 4:85. 2010
    ..We investigated the 'differentiation trajectories' of the hematopoietic system considering a genome-wide scenario...
  18. pmc MiR-15a and miR-16-1 cluster functions in human leukemia
    George A Calin
    Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:5166-71. 2008
    ..By examining the Gene Ontology (GO) database, a significant enrichment in cancer genes (such as MCL1, BCL2, ETS1, or JUN) that directly or indirectly affect apoptosis and cell cycle was found...
  19. pmc MicroRNAs and cancer: what we know and what we still have to learn
    George A Calin
    Department of Experimental Therapeutics and Cancer Genetics, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Genome Med 1:78. 2009
    ..A report on the Keystone Symposia on MicroRNAs and Cancer, Keystone, Colorado, USA, 10-15 June 2009...
  20. ncbi request reprint Non-coding RNAs: identification of cancer-associated microRNAs by gene profiling
    Jana Ferdin
    Department of Animal Science Biotechnical Faculty, University of Ljubljana, Domzale, Slovenia
    Technol Cancer Res Treat 9:123-38. 2010
    ..Based on the most important findings we discuss the possible use of miRNAs as clinical biomarkers in the management of cancer patients for diagnosis, prognosis, and response to therapy...
  21. pmc MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer
    Maitri Y Shah
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Genome Med 3:56. 2011
    ..These new insights into the roles of miR-221/222 in breast cancer metastasis, drug resistance and RAS pathways could potentially have applications in medical practice...
  22. pmc MicroRNA 29b functions in acute myeloid leukemia
    Ramiro Garzon
    Division of Hematology and Oncology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 114:5331-41. 2009
    ..Together, the data support a tumor suppressor role for miR-29 and provide a rationale for the use of synthetic miR-29b oligonucleotides as a novel strategy to improve treatment response in AML...
  23. pmc Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells
    Maria I Almeida
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 142:886-896.e9. 2012
    ..We analyzed the expression, functions, and mechanisms of miR-28-5p and miR-28-3p in colorectal cancer (CRC) cells...
  24. pmc Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment
    Masato Nishimura
    Departments of 1Gynecologic Oncology, 2Experimental Therapeutics, 3Cancer Biology, and 4Thoracic, Head and Neck Medical Oncology, 5Graduate School of Biomedical Sciences, 6The Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas 7Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 8Department of Obstetrics and Gynecology, The University of Tokushima, Graduate School, Tokushima, Japan 9Department of Surgery, School of Medicine, Gyeongsang National University, Jin ju, South Korea and 10Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Batiment Genopode, Lausanne, Switzerland
    Cancer Discov 3:1302-15. 2013
    ..Our data emphasize the feasibility of combined miRNA-siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases...
  25. pmc mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer
    Giovanni Lanza
    Department of Experimental and Diagnostic Medicine and Interdepartment Center for Cancer Research, University of Ferrara, Ferrara, Italy
    Mol Cancer 6:54. 2007
    ..Colorectal cancer develops through two main genetic instability pathways characterized by distinct pathologic features and clinical outcome...
  26. pmc Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility
    Milena S Nicoloso
    Department of Experimental Therapeutics and the Center for RNA Interference and Non coding RNAs, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Res 70:2789-98. 2010
    ..Therefore, we propose that transcribed target SNPs alter miRNA gene regulation and, consequently, protein expression, contributing to the likelihood of cancer susceptibility, by a novel mechanism of subtle gene regulation...
  27. ncbi request reprint Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas
    George A Calin
    Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 12:215-29. 2007
    ..Our findings argue that ncRNAs and interaction between noncoding genes are involved in tumorigenesis to a greater extent than previously thought...
  28. pmc MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
    Ramiro Garzon
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Blood 111:3183-9. 2008
    ..03; and miR-199a, P = .001, Cox regression). In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations. A small subset of miRNAs is correlated with survival...
  29. pmc microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
    Simona Rossi
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:945-52. 2010
    ..We conclude that the 21FK score represents a useful tool for distinguishing between good-prognosis and poor-prognosis CLL patients...
  30. doi request reprint A miRNA signature associated with human metastatic medullary thyroid carcinoma
    Libero Santarpia
    Departments of Endocrine Neoplasia and Hormonal Disorders Experimental Therapeutics Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Oncology, The University of Naples, Naples, Italy Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, Florence, Italy Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Houston, Texas, USA Department of Oncology, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy Department of Gynecologic Oncology, Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, University of Messina, Messina, Italy Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Relat Cancer 20:809-23. 2013
    ..Our data identify a robust miRNA signature associated with metastatic MTC and distinct biological processes, e.g., TGFβ signalling pathway, providing new potential insights into the mechanisms of MTC metastasis...
  31. pmc Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
    Blood 122:1891-9. 2013
    ..Our findings support the use of cellular and plasma levels of miR-155 as biomarkers for the risk of progression in individuals with MBL, as well as to identify patients with CLL who may not respond well to therapy. ..
  32. pmc Reprogramming of miRNA networks in cancer and leukemia
    Stefano Volinia
    Data Mining for Analysis of Microarrays, Department of Morphology and Embryology, Universita degli Studi, Ferrara 44100, Italy
    Genome Res 20:589-99. 2010
    ..Finally, we experimentally validated the miRNA network with acute lymphocytic leukemia originated in Mir155 transgenic mice. Most of miRNAs deregulated in these transgenic mice were located close to hsa-miR-155 in the cancer network...
  33. pmc Tumour angiogenesis regulation by the miR-200 family
    Chad V Pecot
    Department of Thoracic, Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 950, Houston, Texas 77030, USA
    Nat Commun 4:2427. 2013
    ..The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent. ..
  34. pmc Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer
    Xiao Feng Le
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 7:e41170. 2012
    ....
  35. pmc Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes
    George A Calin
    Departments of Experimental Therapeutics and Cancer Genetics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 114:4761-70. 2009
    ....
  36. pmc Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
    Tetsuya Ueda
    Department of Molecular Virology, Immunology, Ohio State University, Columbus, OH 43210, USA
    Lancet Oncol 11:136-46. 2010
    ..We aimed to assess the relation between microRNA expression and progression and prognosis of gastric cancer...
  37. pmc Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer
    Sylwia E Wojcik
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Carcinogenesis 31:208-15. 2010
    ....
  38. ncbi request reprint Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas
    Arianna Bottoni
    Department of Biomedical Sciences and Advanced Therapies, Section of Endocrinology, University of Ferrara, Ferrara, Italy
    J Cell Physiol 210:370-7. 2007
    ..Predictive miRNAs could be potentially useful diagnostic markers, improving the classification of pituitary adenomas...
  39. pmc Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties
    Joseph H Taube
    1 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Center for Stem Cells and Developmental Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Sci Rep 3:2687. 2013
    ..Our data suggest that restoring miR-203 expression levels may inhibit metastasis and combat deregulated Wnt signaling. ..
  40. doi request reprint RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment
    Riccardo Spizzo
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S313-8. 2009
    ..In this review, we focus on the possible use of miRNAs or compounds interacting with miRNAs as new therapeutic agents in cancer patients...
  41. pmc Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia
    Muller Fabbri
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    JAMA 305:59-67. 2011
    ....
  42. pmc CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations
    Roxana S Redis
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 4:1748-62. 2013
    ..Additionally, we found that CCAT2 upregulates cell migration and downregulates chemosensitivity to 5'FU in a rs6983267-independent manner. ..
  43. pmc miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma
    Jun Wei
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer Res 73:3913-26. 2013
    ..Our findings highlight the potential application of miR-124 as a novel immunotherapeutic agent for neoplasms and serve as a model for identifying miRNAs that can be exploited as immunotherapeutics...
  44. pmc A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation
    Guohui Wan
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    EMBO J 32:2833-47. 2013
    ..On the basis of these results, we propose that lncRNA-JADE is a key functional link that connects the DDR to histone H4 acetylation, and that dysregulation of lncRNA-JADE may contribute to breast tumorigenesis. ..
  45. pmc MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
    Muller Fabbri
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, and College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:15805-10. 2007
    ..These findings support a role of miR-29s in epigenetic normalization of NSCLC, providing a rationale for the development of miRNA-based strategies for the treatment of lung cancer...
  46. pmc PD-L1 expression and prognostic impact in glioblastoma
    Edjah K Nduom
    Departments of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas E K N, J W, N K Y, N H, L Y K, K G, X L, A B H Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas S Z Center for RNA Interference and Non Coding RNAs, The University of Texas M D Anderson Cancer Center, Houston, Texas C I Flow Cytometry and Cell Imaging Core Facility, The University of Texas M D Anderson Cancer Center, Houston, Texas J K B Neuropathology, The University of Texas M D Anderson Cancer Center, Houston, Texas G N F Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas G A C Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas C A C Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas C C, K R Lion Biotechnologies, Woodland Hills, California J Q C, L R Dept of Immunology, H Lee Moffitt Cancer Center, Tampa, Florida J Q C, North Carolina 27157
    Neuro Oncol 18:195-205. 2016
    ..Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At issue is the validation of PD-L1 biomarker assays and prognostic impact...
  47. pmc A microRNA expression signature of human solid tumors defines cancer gene targets
    Stefano Volinia
    Department of Molecular Virology, Immunology, and Medical Genetics and Cancer Comprehensive Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 103:2257-61. 2006
    ..Our results indicate that miRNAs are extensively involved in cancer pathogenesis of solid tumors and support their function as either dominant or recessive cancer genes...
  48. ncbi request reprint Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer
    Fabio Petrocca
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 66:10287-91. 2006
    ....
  49. ncbi request reprint MicroRNA expression and function in cancer
    Ramiro Garzon
    Department of Virology, Immunology and Human Genetics, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Trends Mol Med 12:580-7. 2006
    ..Here, we summarize miRNA-profiling studies in human malignancies and examine the role of miRNAs in the pathogenesis of cancer. We also discuss the implications of these findings for the diagnosis and treatment of cancer...
  50. doi request reprint MicroRNAs
    Muller Fabbri
    Human Cancer Genetics, Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, USA
    Cancer J 14:1-6. 2008
    ..miRNA expression levels have diagnostic and prognostic implications, and their roles as anticancer therapeutic agents is promising and currently under investigation...
  51. pmc Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation
    Deepa Sampath
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:3744-53. 2009
    ..Consequently, chemotherapeutic drugs that activate miR106b could initiate a p53-independent mechanism that targets CLL cells...
  52. pmc Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer
    Angela N Bartley
    Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, 70030, USA
    Clin Cancer Res 17:7283-93. 2011
    ..MicroRNAs are potential biomarkers and therapeutic targets and agents, but limited information on microRNAome alterations during progression in the well-known adenoma-adenocarcinoma sequence is available to guide their usage...
  53. pmc miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
    Rajesha Rupaimoole
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Discov 6:235-46. 2016
    ..Here, we discuss the complex protumorigenic symbiotic role between tumor cells, the tumor microenvironment, and miRNA deregulation...
  54. pmc Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma
    Shuo Xu
    Affiliations of authors Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China SX, X GL, Department of Neurosurgery SX, JW, FW, L YK, X yL, EN, KG, TD, YY, FFL, GR, ABH, Department of Biostatistics WQ, Department of Pathology GNF, and Department of Experimental Therapeutics GAC, University of Texas M D Anderson Cancer Center, Houston, TX Baylor College of Medicine, Houston, TX NKY Texas A and M University College of Veterinary Medicine and Biomedical Sciences, College Station, TX VF
    J Natl Cancer Inst 106:. 2014
    ....
  55. pmc MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
    Jun Wei
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas J W, E K N, L Y K, Y H, S X, K G, X L, N H, A B H Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas W Q, S Z Center for RNA Interference and Non Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas C I Departments of Neuropathology, The University of Texas MD Anderson Cancer Center, Houston, Texas G N F Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas M R G Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas W O Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas G A C Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China S X
    Neuro Oncol 18:639-48. 2016
    ..MicroRNAs (miRNAs) can modulate multiple gene transcripts including possibly more than one immune checkpoint and could be exploited as immune therapeutics...
  56. pmc CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
    Hui Ling
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Genome Res 23:1446-61. 2013
    ..Our results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer pathogenesis, and provide an alternative explanation of the SNP-conferred cancer risk. ..
  57. doi request reprint MicroRNAs as new players in the genomic galaxy and disease puzzles
    Elisa Barbarotto
    Department of Morphology and Embryology, University of Ferrara, Ferrera, Italy
    Clin Transl Sci 1:50-6. 2008
    ..This review describes the role of miRNAs in human disease, methodology for evaluating miRNA gene expression, and the potential role of miRNAs as therapeutic agents and targets for the treatment of disease...
  58. pmc The role of microRNA genes in papillary thyroid carcinoma
    Huiling He
    Human Cancer Genetics Program, Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 102:19075-80. 2005
    ..We conclude that up-regulation of several miRs and regulation of KIT are involved in PTC pathogenesis, and that sequence changes in genes targeted by miRNAs can contribute to their regulation...
  59. ncbi request reprint Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181
    Yuri Pekarsky
    Comprehensive Cancer Center, Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, OSU School of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 66:11590-3. 2006
    ..Our results suggest that Tcl1 expression in CLL is, at least in part, regulated by miR-29 and miR-181 and that these microRNAs may be candidates for therapeutic agents in CLLs overexpressing Tcl1...
  60. pmc The mix of two worlds: non-coding RNAs and hormones
    Maitri Y Shah
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nucleic Acid Ther 23:2-8. 2013
    ..We also provide a brief overview of their identification, processing, and potential functions and applications in human diseases...
  61. pmc Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer
    Lianjin Jin
    Department of Biochemistry and Molecular Biology and Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Cancer Res 73:2884-96. 2013
    ..Because anti-miR-27b compounds that suppress miR-27b inhibit tumor growth, the anti-miR-27b seems to be a good candidate for the development of new antitumor therapies...
  62. doi request reprint Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications
    Simona Rossi
    Department of Experimental Therapeutics, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Mamm Genome 19:526-40. 2008
    ..These types of studies are the first step toward discoveries leading to novel approaches for cancer therapies...
  63. doi request reprint MicroRNAs in Cancer
    Ramiro Garzon
    Department of Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Annu Rev Med 60:167-79. 2009
    ..In this review, we briefly describe miRNA biogenesis and discuss how miRNAs can act as oncogenes and tumor suppressors. We also address the role of miRNAs in the diagnosis, prognosis, and treatment of cancer...
  64. ncbi request reprint Beyond genomics: interpreting the 93% of the human genome that does not encode proteins
    Muller Fabbri
    Ohio State University, Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, 1060 Biomedical Research Tower, 460 West 12th Avenue, Columbus, OH 43210, USA
    Curr Opin Drug Discov Devel 13:350-8. 2010
    ..This review focuses on the role of ncRNAs in human carcinogenesis and describes why deciphering the function of these RNAs might lead to the development of new anticancer drugs...
  65. doi request reprint MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases
    Julianna K Edwards
    David H Koch Center, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Cardiovasc Transl Res 3:271-9. 2010
    ..This review focuses on the identification of aberrant posttranscriptional regulators (miRNAs and UCGs) in cancer and cardiovascular disease and addresses the applications of this work towards diagnosis and therapy...
  66. doi request reprint Epigenetics and miRNAs in human cancer
    Muller Fabbri
    Department of Molecular Virology, Ohio State University, Columbus, OH, USA
    Adv Genet 70:87-99. 2010
    ..The result of this epigenetic-miRNA interaction is a new layer of complexity in gene regulation, whose comprehension opens new avenues to understand human cancerogenesis and to achieve new cancer treatments...
  67. pmc H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer
    Masahisa Ohtsuka
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    EBioMedicine 13:113-124. 2016
    ..We further explored the clinical relevance of above mechanisms in clinical samples, and showed that combined analysis of H19 with its targets improved prognostic value of H19 in CRC...
  68. pmc Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia
    Ping Li
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e64678. 2013
    ..Finally, STAT3-small hairpin RNA downregulated miR-155 gene expression, suggesting that constitutively activated STAT3 binds to the miR-155 gene promoter. Together, these results suggest that STAT3 activates miR-155 in CLL cells...
  69. pmc Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma
    Nazila Nouraee
    Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Department of Experimental Therapeutics, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States of America
    PLoS ONE 8:e73009. 2013
    ..MiR-21 is an oncomir expressed by malignant cells and/or tumor microenvironment components. In this study we focused on understanding the effects of stromal miR-21 on esophageal malignant cells...
  70. ncbi request reprint Regulatory mechanisms of microRNAs involvement in cancer
    Muller Fabbri
    Ohio State University, Comprehensive Cancer Center, Columbus, OH 43210, USA
    Expert Opin Biol Ther 7:1009-19. 2007
    ..In this review, the authors analyse the regulatory mechanisms of the main miRNA genes involved in human tumourigenesis...
  71. pmc UCbase & miRfunc: a database of ultraconserved sequences and microRNA function
    Cristian Taccioli
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Nucleic Acids Res 37:D41-8. 2009
    ..The current release contains over 2000 sequences from three species (human, mouse and rat). As a web application, UCbase & miRfunc is platform independent and it is accessible at http://microrna.osu.edu/.UCbase4...
  72. pmc GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic potentials
    Esmerina Tili
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Biological Research Tower, Columbus, OH 43210, USA
    Nucleic Acids Res 38:7673-88. 2010
    ....
  73. doi request reprint High-throughput profiling in the hematopoietic system
    Muller Fabbri
    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, USA
    Methods Mol Biol 667:79-91. 2010
    ..These techniques provide the basis for further investigations focused on the miRNAs, which are most frequently and widely differentially expressed under the different investigated conditions...
  74. doi request reprint MicroRNAs and cancer--new paradigms in molecular oncology
    Massimo Negrini
    Department of Experimental and Diagnostic Medicine, Interdepartment Center for Cancer Research, University of Ferrara, Ferrara 44100, Italy
    Curr Opin Cell Biol 21:470-9. 2009
    ..New diagnostic classifiers based on miRNAs will soon be available for medical practitioners and, even more importantly, miRNAs may become novel anti-cancer tools...
  75. ncbi request reprint MicroRNAs in the pathogeny of chronic lymphocytic leukaemia
    Milena S Nicoloso
    Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 139:709-16. 2007
    ..These discoveries could be exploited for the development of useful markers for diagnosis and prognosis, as well as for the development of new RNA-based cancer therapies...
  76. doi request reprint MicroRNAs in the ontogeny of leukemias and lymphomas
    Muller Fabbri
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:160-70. 2009
    ....
  77. doi request reprint MicroRNAs, ultraconserved genes and colorectal cancers
    Simona Rossi
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Biochem Cell Biol 42:1291-7. 2010
    ....
  78. pmc Regulation of tumor angiogenesis by EZH2
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 18:185-97. 2010
    ..Collectively, these data support the potential for targeting ezh2 as an important therapeutic approach...
  79. doi request reprint MicroRNA profiling in cancer
    Reinhold Munker
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Sci (Lond) 121:141-58. 2011
    ..In the present review, we discuss recent advances in miRNA profiling in human cancer. We discuss both frequent and rare tumour types and give an outlook on future developments...
  80. pmc MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer
    Resham Bhattacharya
    Department of Biochemistry, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:9090-5. 2009
    ..These findings suggest the development of therapeutic strategies by restoring miR-15a and miR-16 expression in ovarian cancer and in other cancers that involve upregulation of Bmi-1...
  81. pmc Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2
    Roxana S Redis
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cell 61:520-34. 2016
    ..These findings uncover a complex, allele-specific regulatory mechanism of cancer metabolism orchestrated by the two alleles of a long ncRNA...
  82. pmc Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis
    Rajesha Rupaimoole
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cell Rep 13:2395-402. 2015
    ..As demonstrated, DOPC nanoparticle-incorporated siRNA-mediated silencing of this lncRNA in vivo provides therapeutic avenue toward modulating lncRNAs in cancer...
  83. pmc MicroRNA fingerprints during human megakaryocytopoiesis
    Ramiro Garzon
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 103:5078-83. 2006
    ..Our data delineate the expression of microRNAs during megakaryocytopoiesis and suggest a regulatory role of microRNAs in this process by targeting megakaryocytic transcription factors...
  84. ncbi request reprint MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005
    ..We could identify miRNAs whose expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index...
  85. doi request reprint MicroRNA involvement in brain tumors: from bench to bedside
    Milena S Nicoloso
    Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Brain Pathol 18:122-9. 2008
    ..Furthermore, new therapeutic strategies involving miRNA silencing or miRNA mimics could be proposed based on the roles of these small non-coding RNAs as oncogenes and tumor suppressors in brain tumors...
  86. doi request reprint MicroRNAs--the micro steering wheel of tumour metastases
    Milena S Nicoloso
    Experimental Therapeutics Department, MD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    Nat Rev Cancer 9:293-302. 2009
    ....
  87. pmc Coordinated targeting of the EGFR signaling axis by microRNA-27a*
    Xiaoli Wu
    Department of Head and Neck Surgery, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:1388-98. 2013
    ..These findings identify miR-27a* as a functional star sequence that exhibits novel coordinated regulation of the EGFR pathway in solid tumors and potentially represents a novel therapeutic option. ..
  88. pmc Principles of microRNA involvement in human cancers
    Hui Ling
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Chin J Cancer 30:739-48. 2011
    ..Also, we orient the reader to several additional reviews that may provide a deeper understanding of this new and exciting field of research...
  89. pmc MicroRNAs and other non-coding RNAs as targets for anticancer drug development
    Hui Ling
    1 Experimental Therapeutics and Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA 2
    Nat Rev Drug Discov 12:847-65. 2013
    ....
  90. ncbi request reprint Non-coding RNAs for medical practice in oncology
    Tetsuro Setoyama
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Keio J Med 60:106-13. 2011
    ..These discoveries could be exploited for the development of useful markers for diagnosis and prognosis in cancer, as well as for the development of new RNA-based cancer therapies...
  91. ncbi request reprint MicroRNA signatures in human cancers
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Nat Rev Cancer 6:857-66. 2006
    ..In addition, profiling has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer...
  92. pmc Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics, Colleges of Medicine and Public Health, The Ohio State University, Columbus, Ohio, USA
    J Clin Invest 117:2059-66. 2007
    ..The identification of such abnormalities has a clear diagnostic and prognostic significance, and there are ever increasing examples of links between certain human cancers and modifications at microRNA loci...
  93. ncbi request reprint The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Wiseman Hall Room 385K, 400 12th Avenue, Ohio State University, Columbus, OH 43210, USA
    Best Pract Res Clin Haematol 20:425-37. 2007
    ..Conceivably, these miRNAs might be used to target BCL2 or TCL1 for therapy of this disease...
  94. doi request reprint MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift
    Muller Fabbri
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Carcinogenesis 30:912-7. 2009
    ..Furthermore, we propose that sequence variations in miRNAs or interactor sites located in mRNAs can be involved in cancer predisposition...
  95. doi request reprint Multiple approach to analyzing the role of microRNAs in apoptosis
    Riccardo Spizzo
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Methods Mol Biol 559:219-45. 2009
    ..Our proposed method for doing this is suitable for both discovery of apoptotic pathways that regulate miRNAs and finding new miRNAs able to induce apoptosis...
  96. pmc PDGF induced microRNA alterations in cancer cells
    Minghai Shao
    Department of Medicine, Indiana University School of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Nucleic Acids Res 39:4035-47. 2011
    ..We propose that PDGF-regulated gene transcription involves alterations in non-coding RNAs and provide evidence for a miR-dependent feedback mechanism balancing growth factor receptor signaling in cancer cells...
  97. doi request reprint miRNAs and long noncoding RNAs as biomarkers in human diseases
    Katrien Van Roosbroeck
    Department of Experimental Therapeutics, Unit 1950, The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, TX 77054, USA
    Expert Rev Mol Diagn 13:183-204. 2013
    ..The authors discuss the established methods and provide a selection of emerging new techniques that can be used to detect and quantify ncRNAs. Finally, the authors discuss ncRNAs as a new strategy for therapeutic interventions...
  98. pmc Cross talk between microRNA and coding cancer genes
    Tanja Kunej
    Department of Animal Science, Biotechnical Faculty, University of Ljubljana, Domzale, Slovenia
    Cancer J 18:223-31. 2012
    ....
  99. ncbi request reprint MicroRNAs: fundamental facts and involvement in human diseases
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Birth Defects Res C Embryo Today 78:180-9. 2006
    ..Furthermore, we discuss the deregulation of miRNAs in human diseases and their involvement in tumorigenesis...
  100. ncbi request reprint MicroRNAs and cancer: profile, profile, profile
    Elisa Barbarotto
    Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 122:969-77. 2008
    ..Therefore, miRNAs fingerprinting represents a new addition to the tools to be used by medical oncologists...
  101. ncbi request reprint Potential therapeutic applications of miRNA-based technology in hematological malignancies
    Elisa Barbarotto
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Pharm Des 14:2040-50. 2008
    ..Here, we provide background on the biogenesis and function of miRNAs and discuss potential therapeutic applications of miRNA-based technology in hematological malignancies...

Research Grants1

  1. MicroRNAs and other non-coding RNAs in Colorectal Metastasis
    EDMUND S KOPETZ; Fiscal Year: 2010
    ..The final results of the described tasks will reveal new markers for molecular diagnosis and prognosis and new targets for drug therapy. ..